Very unexpected to call off the ACCELERATE evacetrapib trial now, since on July 27, 2015 the ACCELERATE study data monitoring committee just recommended continuing the trial! I guess they changed their minds less than 3 months later.

Just one small correction. In addition to Merck's anacetrapib that is still in Phase III, there is another "promising" CETP inhibitor from Dezima called TA-8995 that is in Phase II right now. Dezima was just recently purchased by Amgen (see this story for reference).